Fairvalue-Calculator Fairvalue-Calculator

Chongqing Taiji Industry(Group) Co (600129) Fair Value & Analysis

Healthcare · CN · Market cap 7.4B CNY

Price¥12.70
Fair Value¥4.81
Upside-62.1%
Quality92/100
Evidence: High Range ¥3.61 – ¥6.01

Analysis

Chongqing Taiji Industry(Group) Co (600129) currently trades at ¥12.70, while our model-based Fair Value estimate is ¥4.81 — implying the stock looks roughly 62.1% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Chongqing Taiji Industry(Group) Co.,Ltd, together with its subsidiaries, engages in the production and sales of Chinese and western medicine products in China and internationally. It operates through Pharmaceutical Industry; Pharmaceutical Business; Chinese medicinal materials Resources; Big Health and International; and Service Industry and Others segments. The company offers respiratory system, digestive system and metabolic, nervous system, cardiovascular and cerebrovascular, big health, anti-infective, anti-tumor, immunomodulatory drugs; and anti-aging products. It also engages in accommodation, loading and unloading, warehousing, catering, retail, agriculture, wholesale, and aquaculture activities; and research and development of medicinal herb planting. Chongqing Taiji Industry(Group) Co.,Ltd was incorporated in 1979 and is headquartered in Chongqing, China.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.